Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals UTB by Quarter
UTB — Portion that would impact effective tax rate if recognized ($M) ($M)
Vertex Pharmaceuticals UTB: $439M in Q2 2026, up 6.6% from a year earlier. That is the highest of the 28 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Income Taxes).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB — Portion that would impact effective tax rate if recognized ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 439 | +6.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 420 | +17.6% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 437 | +27.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 422 | +22.4% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 412 | +33.2% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 357 | +18.5% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 341 | +18.3% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 345 | +40.4% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 309 | +23.5% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 302 | +29.9% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 289 | +38.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 245 | +69.4% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 250 | +72.5% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 232 | +69.0% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 209 | +61.0% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 145 | +62.8% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 145 | +71.8% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 137 | +68.0% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 130 | +70.8% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 89 | +20.6% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 84.5 | +23.5% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 81.8 | +90.2% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 75.8 | +123.6% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2020 | Sep 30, 2020 | 73.8 | – | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 68.4 | – | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 43 | – | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 33.9 | +73.8% | Form 10-K (filed 2022-02-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 19.5 | – | Form 10-K (filed 2021-02-11) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals UTB ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/utb-etr-impact
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.